• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    cbdMD Reports Preliminary Unaudited Fourth Quarter and Fiscal 2025 Results

    11/21/25 8:30:00 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $YCBD alert in real time by email

    Year Over Year Net Sales Expected to Remain in line with Prior Year

    Year Over Year Quarterly Net Sales Expected to Increase Between 3% and 5%

    CHARLOTTE, N.C., Nov. 21, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD) (the "Company") one of the most trusted and recognized cannabidiol (CBD) brands in the United States with a comprehensive line of domestically produced CBD products and Farm Bill-compliant Delta-9 offerings, today reported the following preliminary financial results for the fourth quarter of fiscal 2025 and the year ended September 30, 2025.

    cbdMD logo

    • Net sales revenue for fiscal 2025 is expected to range between $19.1 and $19.3 million as compared to $19.5 million in fiscal 2024.
    • Net sales revenue for the fourth quarter of fiscal 2025 is expected to range between $4.7 and $4.9 million compared to $4.6 million in the fourth quarter of fiscal 2024.
    • Net Loss for fiscal 2025 is expected to improve from $3.7 million to a range of between $1.9 and $2.1 million.

    "Over the past year, cbdMD has taken decisive action to strengthen the business, sharpen our operating model, and create a more stable foundation for long-term growth. These efforts are reflected in our results. While many of our public peers reported 8–10% declines in our fiscal fourth quarter and trailing twelve months, we achieved positive sequential and year over year revenue growth in the fourth quarter and essentially flat year-over-year sales, a clear sign that our strategy is taking hold. We expect continued earnings improvement for fiscal 2025 over 2024, driven by disciplined cost management and a focus on profitable growth. I'm proud of our team's performance this year and the momentum we are building across the organization. As we look ahead to our mid-December earnings call, we are energized by what we've accomplished and confident in our ability to steer a path forward. Our team has a multi-year track record of improving the business, and we remain relentless in our commitment to navigating a complex environment and delivering a durable, long-term business for shareholders," said Ronan Kennedy, CEO & CFO of cbdMD.

    About cbdMD, Inc.

    cbdMD, Inc. (NYSE:YCBD) is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, and an array of Farm Act compliant Delta 9 products. Our Herbal Oasis Brand is a line of premium hemp-derived THC seltzers crafted to elevate everyday experiences. Our Paw CBD brand of pet products includes veterinarian-formulated products, and our ATRx brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown hemp products as well as our other brands, please visit www.cbdmd.com, www.herbaloasis.com, www.pawcbd.com, or ATRxlabs.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retail outlets that carry cbdMD's products.

    Note About Preliminary Results

    The preliminary unaudited financial results presented in this release are preliminary and may change. The preliminary unaudited financial information includes calculations or figures that have been prepared internally by management and have not been reviewed or audited by our independent registered public accounting firm. There can be no assurance that cbdMD, Inc.'s actual results for the periods presented herein will not differ from the preliminary unaudited financial data presented herein, and such changes could be material. This preliminary unaudited financial data should not be viewed as a substitute for full audited consolidated financial statements prepared in accordance with GAAP and is not necessarily indicative of the results to be achieved for any future period. Our audited consolidated financial statements for the fiscal year ended September 30, 2025 will be contained in our Annual Report on Form 10-K to be filed with the Securities and Exchange Commission on or before December 29, 2025.

    Forward-Looking Statements

    This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to expectations on our ability to continue as a going concern, increasing our revenues, potential changes in federal laws, product development, regaining compliance with NYSE American continued listing requirements and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 as filed with the Securities and Exchange Commission (the "SEC") on December 17, 2024, and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.

    1 THC-free is defined as below the level of detection using validated scientific analytical methods.

    Contact Information:

    cbdMD, Inc.

    Ronan Kennedy

    Chief Executive Officer and Chief Financial Officer

    [email protected]

    (704) 445-3064

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cbdmd-reports-preliminary-unaudited-fourth-quarter-and-fiscal-2025-results-302622485.html

    SOURCE cbdMD, Inc.

    Get the next $YCBD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YCBD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $YCBD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald resumed coverage on cbdMD with a new price target

    Cantor Fitzgerald resumed coverage of cbdMD with a rating of Neutral and set a new price target of $3.25 from $4.10 previously

    6/18/21 6:26:36 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Cantor Fitzgerald reiterated coverage on cbdMD with a new price target

    Cantor Fitzgerald reiterated coverage of cbdMD with a rating of Neutral and set a new price target of $4.30 from $3.60 previously

    1/29/21 4:54:10 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Crosnoe Clark R. sold $1,276,842 worth of shares (550,701 units at $2.32) (SEC Form 4)

    4 - cbdMD, Inc. (0001644903) (Issuer)

    12/19/25 9:16:26 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    CEO and CFO Kennedy Thomas Ronan was granted 445,000 shares, increasing direct ownership by 648% to 513,722 units (SEC Form 4)

    4 - cbdMD, Inc. (0001644903) (Issuer)

    12/2/25 6:29:31 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Porter Jeffrey H was granted 1,572 shares (SEC Form 4)

    4 - cbdMD, Inc. (0001644903) (Issuer)

    5/20/25 5:23:40 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    SEC Filings

    View All

    SEC Form 10-Q filed by cbdMD Inc.

    10-Q - cbdMD, Inc. (0001644903) (Filer)

    2/17/26 4:06:16 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form PRE 14A filed by cbdMD Inc.

    PRE 14A - cbdMD, Inc. (0001644903) (Filer)

    1/30/26 8:22:40 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form S-1 filed by cbdMD Inc.

    S-1 - cbdMD, Inc. (0001644903) (Filer)

    1/22/26 9:14:20 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

    CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss the company's December 31, 2025 first quarter financial results and business progress. CONFERENCE CALL DETAILS Tuesday, February 17, 2026, 4:20 p.m. Eastern Time USA/Canada: 888-880-3330 Webcast/Webcast Replay link - available through February 17, 2027: https://app.webinar.net/YzX7D4ynvN2 About cbdMD, Inc.

    2/12/26 5:31:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD's Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum

    CHARLOTTE, N.C., Feb. 2, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), a leading innovator in wellness and hemp-derived consumer products, today announced a major distribution expansion for its Herbal Oasis THC-infused social seltzer ("Oasis") through an expanded partnership with Morales Beverage Group ("MBG"). The agreement extends Oasis into Louisiana, strengthening the brand's regional footprint across the Gulf South and creating a more contiguous platform for continued Southeast growth, following strong early performance in Texas. With MBG's established statewide distribut

    2/2/26 9:00:00 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Financials

    Live finance-specific insights

    View All

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD, Inc. to Host Conference Call to Discuss December 31, 2025 First Quarter Results

    CHARLOTTE, N.C., Feb. 12, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 17, 2026, to discuss the company's December 31, 2025 first quarter financial results and business progress. CONFERENCE CALL DETAILS Tuesday, February 17, 2026, 4:20 p.m. Eastern Time USA/Canada: 888-880-3330 Webcast/Webcast Replay link - available through February 17, 2027: https://app.webinar.net/YzX7D4ynvN2 About cbdMD, Inc.

    2/12/26 5:31:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Reports Third Consecutive Year of Operating Improvement, Strengthens Balance Sheet, and Regains NYSE American Continued Listing Compliance

    CHARLOTTE, N.C., Dec. 19, 2025 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with hemp derived THC beverage line Herbal Oasis today announced our financial results for the full fiscal year ended September 30, 2025. For fiscal year 2025, cbdMD delivered its third consecutive year of operational and financial improvement, reflecting disciplined cost management, focused execution, and continued investment in quality and science. The Company

    12/19/25 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Leadership Updates

    Live Leadership Updates

    View All

    cbdMD, Inc. Announces Shareholder Approval of Automatic Conversion of Series A Preferred Stock and Other Results from Annual Meeting

    Charlotte, North Carolina--(Newsfile Corp. - April 10, 2025) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA) (the "Company" or "cbdMD") one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its functional mushroom brand ATRx Labs and emerging THC-infused seltzer brand Herbal Oasis announced today that at the Company's annual meeting of shareholders held on April 10, 2025, that its Common Stock holders and 8% Series A Cumulative Convertible Preferred Stock (the "Preferred Stock") holders approved the automatic conversion (the "Conversion") of shares of the Company's Preferred Stock into shares of the Comp

    4/10/25 5:57:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Announces Partnership with Medical Advisor, Dr. Lucille Vega

    Charlotte, North Carolina--(Newsfile Corp. - June 22, 2023) - cbdMD (NYSE:YCBD), one of the nation's leading providers of premium cannabidiol (CBD) products, is delighted to announce the appointment of Dr. Lucille Vega as their new medical advisor. This collaboration marks an exciting chapter for both parties, as they play a pivotal role in educating the public about the numerous benefits of CBD and cbdMD's commitment to quality and transparency.As a brand that's renowned for its commitment to quality and innovation, cbdMD's comprehensive line of products spans across various categories and caters to a diverse range of consumer needs. By partnering with Dr. Vega, a highly qualified and passi

    6/22/23 9:00:00 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    cbdMD Welcomes Shannon Charles as Chief Marketing Officer

    Charlotte, North Carolina--(Newsfile Corp. - January 11, 2023) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces the appointment of Shannon Charles as Chief Marketing Officer. Shannon is a veteran in health and wellness with over a decade of success in the Natural Product Industry. She has a proven record in driving growth across B&M retail, warehouse club stores, ecommerce, as well as international markets. Shannon's leadership has supported the successful brand stories of Naturade, NeoCell, and NutraNext, which the latter was ultimately acquired by The Clorox Co during her tenure. "We are thrilled to h

    1/11/23 12:33:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $YCBD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by cbdMD Inc. (Amendment)

    SC 13D/A - cbdMD, Inc. (0001644903) (Subject)

    8/12/22 4:02:14 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13D/A filed by cbdMD Inc. (Amendment)

    SC 13D/A - cbdMD, Inc. (0001644903) (Subject)

    6/21/22 7:52:33 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13D/A filed by cbdMD Inc. (Amendment)

    SC 13D/A - cbdMD, Inc. (0001644903) (Subject)

    5/19/22 4:05:28 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary